InSilico Medicine Overview

  • Founded

  • 2014

Founded
  • Status

  • Private

  • Employees

  • 70

Employees
  • Latest Deal Type

  • Series D

  • Latest Deal Amount

  • $95M

  • Investors

  • 40

InSilico Medicine General Information

Description

Researcher and developer of an artificial intelligence (AI) platform and new drugs designed to deliver breakthrough solutions for cancer, fibrosis, immunity, central nervous system diseases and age-related diseases. The company's platform and drugs leverage next-generation AI systems that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets, design novel molecular structures with desired properties and connect biology, chemistry, and clinical trials analysis, enabling pharmaceutical and academic partners to reduce the time and costs associated with bringing life-saving medications to patients.

Contact Information

Website
www.insilico.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Discovery Tools (Healthcare)
Primary Office
  • Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park
  • Pak Shek Kok, New Territories
  • Hong Kong
  • Hong Kong

InSilico Medicine Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

InSilico Medicine Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC (Series D) 01-Jun-2022 $95M 00000 00000 Completed Clinical Trials - Phase 1
10. Later Stage VC (Series C1) 10-Jan-2022 0000 00000 Completed Clinical Trials - Phase 1
9. IPO 08-Nov-2021 Cancelled Pre-Clinical Trials
8. Later Stage VC (Series C) 01-Jun-2021 00000 00000 00000 Completed Pre-Clinical Trials
7. Later Stage VC (Series B1) 01-Jan-2020 000.00 00000 Completed Pre-Clinical Trials
6. Later Stage VC (Series B) 12-Aug-2019 0000 000.00 Completed Pre-Clinical Trials
5. Early Stage VC (Series A3) 18-Jun-2018 000 000.00 0000 Completed Pre-Clinical Trials
4. Early Stage VC (Series A2) 18-Jul-2017 000 000.00 Completed Pre-Clinical Trials
3. Early Stage VC (Series A1) 27-Feb-2017 $2.8M $14.3M Completed Pre-Clinical Trials
2. Early Stage VC 22-Feb-2017 $10M $11.5M Completed Pre-Clinical Trials
To view InSilico Medicine’s complete valuation and funding history, request access »

InSilico Medicine Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A 000,000 00.000000 00.00 00.00 00 00.00 000
To view InSilico Medicine’s complete cap table history, request access »

InSilico Medicine Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Researcher and developer of an artificial intelligence (AI) platform and new drugs designed to deliver breakthrough solu
Drug Discovery
Hong Kong, Hong Kong
70 As of 2023
00000
0000 0000-00-00
00000000000 00000

000000

ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incidi
000000000 00000 (000
Oxford, United Kingdom
000 As of 0000
00000
000000000 00000

000000

commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit es
0000 000000000
San Francisco, CA
00 As of 0000
00000
0000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

InSilico Medicine Competitors (21)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Exscientia Formerly VC-backed Oxford, United Kingdom 000 00000 000000000 00000
00000000 Venture Capital-Backed San Francisco, CA 00 00000 0000000000 00000
0000000 Venture Capital-Backed Toronto, Canada 00 000.00 00000 000.00
0000000 Venture Capital-Backed South San Francisco, CA 000 00000 00000000000 00000
000000000000 Formerly PE-Backed London, United Kingdom 000 00000 000000000 00000
You’re viewing 5 of 21 competitors. Get the full list »

InSilico Medicine Patents

  • 65

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 10

    Granted

  • 17

    Pending

  • 000

    Expiring in next 12 mo

InSilico Medicine Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220406404-A1 Adversarial framework for molecular conformation space modeling in internal coordinates Pending 09-Jun-2021 000000000
US-20220274959-A1 Analogs for the treatment of disease Active 24-Feb-2021 000000000
US-11530197-B2 Analogs for the treatment of disease Active 24-Feb-2021 0000000000 00
US-20220289723-A1 Analogs for the treatment of disease Active 24-Feb-2021 000000000
US-11530199-B2 Analogs for the treatment of disease Active 24-Feb-2021 A61P13/12 00
To view InSilico Medicine’s complete patent history, request access »

InSilico Medicine Executive Team (9)

Name Title Board Seat Contact Info
Alexander Zhavoronkov Ph.D Co-Founder, Co-Chief Executive Officer & Board Member
Alexander Aliper Ph.D Co-Founder & President
Nirav Jhaveri Chief Financial Officer
Qingsong Zhu Ph.D General Manager & Secretary
Feng Ren Ph.D Chief Scientific Officer, Co-Chief Executive Officer, Head of Drug R&D & Board Member
You’re viewing 5 of 9 executive team members. Get the full list »

InSilico Medicine Board Members (8)

Name Representing Role Since
Alexander Zhavoronkov Ph.D InSilico Medicine Co-Founder, Co-Chief Executive Officer & Board Member 000 0000
Dave Madge WuXi AppTec Board Member 000 0000
Feng Ren Ph.D InSilico Medicine Chief Scientific Officer, Co-Chief Executive Officer, Head of Drug R&D & Board Member 000 0000
Kan Chen Ph.D Qiming Venture Partners Board Member 000 0000
Min Fang Self Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

InSilico Medicine Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

InSilico Medicine Investors (40)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BHR Partners PE/Buyout Minority 000 0000 000000 0
Boston Investments Real Estate Minority 000 0000 000000 0
Ericsenz Capital PE/Buyout Minority 000 0000 000000 0
Fong Capital Partners Growth/Expansion Minority 000 0000 000000 0
Prosperity7 Ventures Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 40 investors. Get the full list »

InSilico Medicine Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000000.00 19-Jul-2018 00000 0000 Other Healthcare Technology Systems 000000000
Juvenescence AI 26-Jul-2017 Joint Venture Drug Discovery 000000000
To view InSilico Medicine’s complete investments history, request access »

Ready to get started?

Request a free trial